10105375In-vivo studies for a quantum optical non-invasive glucose sensorClosedLaunchpadInnovate UKThere is a compelling need for affordable and accessible technologies that can aid in the early diagnosis of medical conditions to prevent ill-health by reducing the existing and future burden of disease, ensuring everyone can live long, healthy lives. These types of solutions are equally important for monitoring long-term health conditions that can be complex and require close management to ensure no negative impact on an individual's health, as well as reducing the impact on healthcare providers' resources; a current issue for increasingly prevalent long-term conditions, such as diabetes. Currently, there are 463M people living with diabetes worldwide and a predicted 700M by 2045\. To manage their condition, people living with diabetes must maintain close glycemic control with frequent glucose measurements. However, current state-of-the-art solutions -- finger prick tests and continuous glucose monitors (CGMs) -- do not support this. Both solutions have their limitations, such as painful measurements that are intrusive to daily life, lack of reusability, inadequate measurement accuracy at low glucose concentrations, skin-irritation, user-wear fatigue, and high-cost barriers. Ultimately, these solutions deter people from making regular glucose measurements, which is the core to good diabetes management. Accessible and user-friendly solutions that encourage frequent measurements are needed to support better management practices, which will reduce the likelihood of complications and reduce the impact of diabetes on individuals and healthcare providers, such as the NHS. The NHS spends £10B (c.10% of the annual budget) tackling the treatment and complications of diabetes. Of this, c.£3B is spent on treating diabetes-related complications and correcting the issues arising from diabetes mismanagement but less than £2.5B is spent on diabetes management. This demonstrates that current state-of-the-art technologies are not conducive to effective diabetes management and that our current reactive approach is flawed. NIQS is developing the future of glucose monitoring; a truly non-invasive, continuous, and accurate glucose sensor. Our solution will provide an affordable, user-friendly alternative which will enable us to adopt a preventative and proactive approach to diabetes management compared to the current state-of-the-art. Our recent efforts culminated in a handheld-sized prototype which demonstrated high measurement accuracy across a broad range of glucose concentrations in an ex-vivo study. This grant will support NIQS' shift into in-vivo (human) studies, our wider commercialisation efforts and accelerate NIQS to market.